Finance
Markets
No recent trading data. The last price we hold for REGN is from Jun 3 (48 days ago). This symbol may be delisted, renamed, or halted — the figures below reflect its last active session, not the current market.

REGN

stock Healthcare Biotechnology
Regeneron Pharmaceuticals
$618.95 +16.03 (+2.66%) Delayed · quoted 47d ago
Healthy 79% Climbing

What the indicators say

Mixed 1 of 5 trend signals bullish
Momentum · RSI 14 Leaning bearish
34
0oversold 30overbought 70100

RSI 34 — soft momentum, not yet oversold.

EMA 21 $654.26
Below
Near-term trend is down
SMA 50 $711.65
Below
Medium-term trend is down
SMA 200 $695.30
Below
Long-term trend is down
50 / 200-day
Golden cross
50-day above the 200-day — bullish
Supertrend $654.17
Downtrend
Price is below the Supertrend band — bearish

A mechanical reading of the chart’s indicators — not investment advice.

Key statsas of Jun 3

The day open and close within the day's range
Low $599.00 High $623.90
Open
$618.95
+2.66%
Close
$618.95
+2.66%
52-week range where the price sits across its year
52w low $476.49 52w high $821.11
Current
$618.95
Prev close
$602.92
Volume 1.15× the 3-month average
0 avg 2× avg
Today
951.54K
3-mo avg
824.73K

Earningscalendar synced from Yahoo 57d ago

Most recent
Apr 2983 days ago
Next expected
Jul 30in 9 days

Recent earnings dates

  • Apr 29 83 days ago
  • Apr 8 104 days ago
  • Jan 30 172 days ago
  • Jan 12 190 days ago

Past earnings dates come from REGN’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.

Fundamentalssynced from SEC 51d ago

Strong

Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), REGN’s fundamentals read as strong overall.

P/E ratio Strong
15.1x

At 15.1x, the price is a reasonable multiple of the company's annual profit.

Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.

Dividend yield Fair
0.00%

This company pays no dividend, common for firms reinvesting their profits back into growth.

The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.

Profit margin Strong
31.4%

A 31.4% margin is strong; the company keeps a healthy slice of every revenue dollar.

The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.

Return on equity Fair
14.4%

A 14.4% return on equity is respectable, in the normal range.

Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.

Return on assets Strong
11.1%

A 11.1% return on assets is strong; the company squeezes good profit from its assets.

Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.

Debt-to-equity Strong
0.30

At 0.30, the company carries less in liabilities than in equity, a conservative balance sheet.

Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.

Current ratio Strong
4.13

At 4.13, short-term assets comfortably cover short-term bills.

Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.

Revenue growth Fair
+1.0%

Revenue grew 1.0% from the prior year: steady, modest expansion.

Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.

Earnings growth Fair
+2.1%

Net income grew 2.1% from the prior year: steady profit expansion.

Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.

Financialssynced from SEC 51d ago

FY2021FY2022FY2023FY2024FY2025
Revenue $16.1B$12.2B$13.1B$14.2B$14.3B
Net income $8.1B$4.3B$4.0B$4.4B$4.5B
Diluted EPS $71.97$38.22$34.77$38.34$41.48
Dividend / share —————
Total assets $25.4B$29.2B$33.1B$37.8B$40.6B
Total liabilities $6.7B$6.6B$7.1B$8.4B$9.3B
Shareholder equity $18.8B$22.7B$26.0B$29.4B$31.3B

Leadershipsynced from SEC 54d ago

  • Pitofsky Jason SVP Controller
  • Bassler Bonnie L Director
  • Ryan Arthur F Director
  • Sing George L Director
  • Thompson Craig B. Director
  • Zoghbi Huda Y Director

Officers and board are drawn from REGN’s recent SEC ownership filings (Forms 3, 4 and 5).

Recent leadership changes

Notable recent eventspast year

  • May 18 New 6-month low (-22% off peak)
  • May 18 −9.8% one-day move
  • Apr 29 −6.2% one-day move
  • Oct 28, 2025 +11.8% one-day move
  • Oct 1, 2025 +6.7% one-day move

Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.

Dividendssynced from Yahoo 52d ago

Pays quarterly Strong
2025 total
$3.52
2026 so far
$1.882 payments
2026 projected
$3.76+6.8% vs 2025

Projection scales REGN’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.

Payment history

  • May 20 $0.94
  • Feb 20 $0.94
  • Nov 20, 2025 $0.88
  • Aug 18, 2025 $0.88
  • May 20, 2025 $0.88
  • Feb 20, 2025 $0.88

Recent SEC filingssynced from SEC 51d ago

© 2026 Isaac Bythewood · Some rights reserved